GlaxoSmithKline’s experimental drug GSK095, a RIP1 inhibitor, is designed to work in tandem with checkpoint-inhibiting medicines in the hopes of empowering the immune system to launch a more aggressive attack against tumors than it does with checkpoint inhibitors alone.